An economic model based on the ECHELON-2 trial demonstrated cost-effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma (PTCL).
Joseph Lee, PhD
Advertisement
Articles by Joseph Lee, PhD
Advertisement
Latest Updated Articles
- Cost-effectiveness of Brentuximab Vedotin With Chemotherapy in Treatment of CD30-Expressing PTCL
Published: February 11th 2020 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
New Legislation Aims to Address Transparency in PBMs as First Major Step in Reform
2
Advances in MASLD and MASH Care Highlight Progress and Persistent Gaps
3
Catchment Areas Shape Diversity and Access in Oncology Trials: Amir Fathi, MD
4
Overcoming Mistrust in Clinical Trial Enrollment Through Community Resources: Susan Vadaparampil, PhD, MPH
5